Innate Pharma (IPHA) Change in Cash (2019 - 2025)

Innate Pharma has reported Change in Cash for 7 years, with the latest figure at -$44.6 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Cash fell 891.34% year-over-year to -$44.6 million; the trailing twelve-month figure through Dec 2025 stood at -$63.7 million (down 92.55% YoY), and the FY2025 full-year result was -$44.6 million, down 891.34% from the prior year.
• Change in Cash for Q4 2025 stood at -$44.6 million, down from -$4.5 million in the prior quarter.
• The five-year high for Change in Cash was -$1076.9 in Q2 2024, with the low at -$44.6 million in Q4 2025.
• Historically, Change in Cash has averaged -$19.5 million across 5 years, with a median of -$14.7 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Cash slumped 1520.02% — and 2024, when it jumped 99.99%.
• Innate Pharma's Change in Cash stood at -$37.8 million in 2021, then surged by 47.27% to -$19.9 million in 2022, then climbed by 26.47% to -$14.7 million in 2023, then soared by 69.31% to -$4.5 million in 2024, then sank by 891.34% to -$44.6 million in 2025.
• The last three Change in Cash figures came in at -$44.6 million (Q4 2025), -$4.5 million (Q4 2024), and -$1076.9 (Q2 2024), per Business Quant data.